Monitor upcoming EMA interactions and any regulatory milestones for vilobelimab or izicopan in AAV. The Tavneos revocation creates a competitive opening, but InflaRx has not yet filed for approval or provided a timeline. Watch for Phase 2/3 data readouts and partnership announcements that could crystallize value.
Price Chart
Executive Summary
InflaRx announced it is assessing a broader development and registrational strategy for ANCA-associated vasculitis (AAV) in Europe following the EMA CHMP recommendation to revoke Tavneos' marketing authorization. The company intends to engage with EMA regarding both vilobelimab (Phase 3-ready in AAV) and izicopan (oral C5aR inhibitor) to determine the most efficient regulatory pathway. This positions InflaRx to potentially capture a significant share of the AAV treatment market, though no concrete financial figures or timelines were provided.
Key Facts
- EMA CHMP recommended revoking Tavneos' marketing authorization in the EU on June 26, 2026, creating a potential market opportunity for InflaRx's C5a/C5aR inhibitors in AAV.
- InflaRx intends to engage with EMA regarding both vilobelimab (anti-C5a antibody, Phase 3-ready in AAV) and izicopan (oral C5aR inhibitor) for AAV.
- Vilobelimab has completed two Phase 2 AAV studies (IXCHANGE in Europe, IXPLORE in the U.S.) showing comparable remission rates to standard-dose glucocorticoids with substantially lower glucocorticoid exposure.
- Izicopan Phase 2 planning in AAV continues uninterrupted across multiple geographies.
- Staidson (collaborator) is conducting a Phase 3 trial of BDB-001 (vilobelimab cell line antibody) in AAV in China, initiated in 2025.
- GOHIBIC (vilobelimab) is approved in the EU for COVID-19 ARDS under exceptional circumstances and has EUA in the U.S. for COVID-19.
Financial Impact
No financial figures provided; potential market opportunity in AAV (rare autoimmune disease) following Tavneos revocation, but no revenue, deal values, or cost estimates disclosed.
Risk Factors
- Regulatory path for vilobelimab/izicopan in AAV is uncertain and may require additional clinical trials.
- InflaRx has no approved product generating significant revenue; GOHIBIC EU approval is under exceptional circumstances with limited commercial uptake.
- Competition from other C5a/C5aR inhibitors or alternative AAV therapies could limit market share.
- Company may need additional financing to fund development; no cash runway disclosed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3319558 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $1.56 | awaiting T+20 | — | $1.58 (+0.96%) |
Oct 22, 2026 4d ago | Press Release | $1.53 | awaiting T+20 | — | $1.58 (+2.94%) |
Oct 2, 2026 24d ago | Press Release | $1.72 | awaiting T+20 | — | $1.58 (−8.43%) |
Oct 1, 2026 25d ago | Press Release | $1.71 | awaiting T+20 | — | $1.58 (−7.89%) |
Aug 14, 2026 10w ago | 424B5 | $2.07 $2.02 | ▲ +2.42% | ▲ +0.44% | $1.58 (+23.91%) |
Aug 13, 2026 10w ago | EFFECT | $2.01 $2.09 | ▼ −3.98% | ▼ −5.73% | $1.58 (+21.64%) |
Aug 6, 2026 11w ago | 6-K | $1.72 $2.23 | ▲ +29.65% | ▲ +29.05% | $1.58 (−8.43%) |
Jun 30, 2026 16w ago | 6-K | $2.33 $1.65 | ▼ −29.18% | ▼ −27.00% | $1.58 (−32.40%) |
Jun 30, 2026 16w ago | Press Release | $2.24 $1.70 | ▼ −24.11% | ▼ −23.08% | $1.58 (−29.69%) |
May 6, 2026 24w ago | 424B5 | $2.65 $2.06 | ▲ +22.26% | ▲ +25.40% | $1.58 (+40.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers